设计,合成和评估一种强效和选择性的ROCK2抑制剂,用于治疗无氧性皮肤炎.
Churu Mao1, Shuai Zhan1, Zhangyun Fang1
1Institute of Marine Biology and Pharmacology, Ocean College, Zhejiang University, Zhoushan 316021, China.
Journal of medicinal chemistry
|January 23, 2026
概括
一种新药,10d针对ROCK2治疗亚托皮性皮肤炎 (AD). 这种选择性抑制剂通过降低S100A9的调节,在临床前模型中显示出卓越的疗效和安全性,为AD提供了一种新的治疗方法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 结构生物学 结构生物学
背景情况:
- 亚托皮炎 (AD) 由于现有治疗方法的有效性和安全性有限,因此存在重大治疗挑战.
- 目前对阿尔茨海默病的治疗方法往往无法有效地解决潜在的疾病机制.
- 对于针对阿尔茨海默病的特定分子通路的新型治疗策略有着至关重要的需求.
研究的目的:
- 确定和开发一种新,强效和选择性ROCK2抑制剂,用于治疗亚托皮炎.
- 探索在AD中准ROCK2-S100A9轴的治疗潜力.
- 在AD的临床前模型中评估新发现的ROCK2抑制剂,化合物10d的疗效和安全性.
主要方法:
- 以结构为导向的ROCK2分析,以确定药物设计的独特结构特征.
- 虚拟选,以发现向ROCK2.2已识别的疏水表面 (S1) 的小分子.
- 化合物10d在ROCK2抑制功效和选择性方面与参考化合物KD025.25相比进行了体外表征.
- 在MC903诱导的皮炎小鼠模型中评估化合物10d的疗效和安全性.
- 机制研究以阐明ROCK2抑制10d的下游效应,重点关注S100A9.9.
主要成果:
- 在ROCK2上识别了一个独特的疏水表面 (S1),使得基于结构的药物设计成为可能.
- 发现化合物10d,一种高效和选择性的ROCK2抑制剂,其性能比KD025.25有所改善.
- 在小鼠模型中证明了10d在抑制炎症和改善AD病理方面的显著疗效.
- 在临床前AD模型中观察到化合物10d的有利安全概况.
- 证实了10d通过降低S100A9的调节来减轻AD病理,验证了ROCK2-S100A9通路.
结论:
- 化合物10d是一种高度活性和选择性的ROCK2抑制剂,具有针对亚托皮炎的显著治疗潜力.
- ROCK2-S100A9轴代表了AD的新和有前途的治疗标.
- 这项研究为阿尔茨海默氏症的ROCK2向治疗提供了第一个证据,并将10d确定为进一步开发的领先候选人.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
580
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
580
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Eukaryotic Transcription Inhibitors
10.9K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
Group Design
10.3K
The most basic experimental design involves two groups: the experimental group and the control group. The two groups are designed to be the same except for one difference— experimental manipulation. The experimental group gets the experimental manipulation—that is, the treatment or variable being tested—and the control group does not. Since experimental manipulation is the only difference between the experimental and control groups, we can be sure that any differences between...
10.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
469
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
469
Dehydration Synthesis
149.0K
Overview
Dehydration synthesis (also called a condensation reaction) is the chemical process in which two molecules covalently link together to form a new molecule, along with the release of a water molecule. Many physiologically important compounds form by dehydration synthesis reactions, such as complex carbohydrates, proteins, DNA, and RNA.
Synthesis of carbohydrates
Sugar molecules are covalently linked together by dehydration synthesis. During the reaction, the hydroxyl (-OH) group from...
Dehydration synthesis (also called a condensation reaction) is the chemical process in which two molecules covalently link together to form a new molecule, along with the release of a water molecule. Many physiologically important compounds form by dehydration synthesis reactions, such as complex carbohydrates, proteins, DNA, and RNA.
Synthesis of carbohydrates
Sugar molecules are covalently linked together by dehydration synthesis. During the reaction, the hydroxyl (-OH) group from...
149.0K


